» Articles » PMID: 8393652

Outcomes After Curative Resections of Cholangiocarcinoma

Overview
Journal Arch Surg
Specialty General Surgery
Date 1993 Aug 1
PMID 8393652
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To elucidate the clinical and pathologic features of extrahepatic cholangiocarcinomas and to identify prognostic variables in patients treated surgically.

Design: Retrospective review of clinical records of patients undergoing surgical exploration for cholangiocarcinoma, with univariate and multivariate analyses of the clinical and pathologic factors that influenced patient survival.

Setting: Mayo Clinic, Rochester, Minn.

Study Participants: One hundred seventy-one patients undergoing operative intervention for diagnostic, palliative, or curative reasons between 1976 and 1985. Follow-up was complete until death or for a minimum of 5 years for surviving patients.

Intervention: A curative surgical resection was performed in 29% of patients, while the remainder underwent tumor biopsy or a palliative procedure.

Main Outcome Measure: Patient survival following operative treatment.

Results: The operative mortality in this patient cohort was 5% and median survival was 13 months. Overall 5-year survival was 16%, with 44% of patients having a curative resection still alive at 5 years. Using univariate analysis, curative resection, tumor stage, Eastern Cooperative Oncology Group performance status, total bilirubin concentration, lymph node status, liver invasion, tumor morphology, tumor grade, and site of tumor origin were significant determinants of prognosis. Using the Cox proportional hazards model for multivariate analysis, curative resection, Eastern Cooperative Oncology Group performance status, total bilirubin concentration, and tumor grade were the only variables predictive of patient outcome. A curative resection of a proximal cholangiocarcinoma had a similar chance of providing long-term survival as a curative distal ductal resection.

Conclusions: Although the tumor extent and the patient's overall health will affect outcome, curative resection for cholangiocarcinoma at all sites should be undertaken since this treatment offers the best chance for long-term survival.

Citing Articles

Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers.

Okubo A, Matsumoto S, Tamamura H, Sato Y, Asahi S, Tatebe H Radiat Oncol. 2024; 19(1):160.

PMID: 39538328 PMC: 11562633. DOI: 10.1186/s13014-024-02550-2.


A Case of Cholecystitis Camouflaging Cholangiocarcinoma.

Paranji S, Vegunta R, Pellegrino C Cureus. 2024; 16(3):e55448.

PMID: 38571825 PMC: 10987331. DOI: 10.7759/cureus.55448.


Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma.

Bekric D, Tornesello M, Ocker M, Mayr C, Kiesslich T, Neureiter D Front Cell Dev Biol. 2023; 11:1320084.

PMID: 38020902 PMC: 10656678. DOI: 10.3389/fcell.2023.1320084.


Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.

Bekric D, Neureiter D, Ablinger C, Dobias H, Beyreis M, Ritter M Cancers (Basel). 2023; 15(5).

PMID: 36900361 PMC: 10000745. DOI: 10.3390/cancers15051569.


Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis.

de Savornin Lohman E, Belkouz A, Nuliyalu U, Groot Koerkamp B, Klumpen H, Reuver P J Gastrointest Oncol. 2023; 13(6):3227-3239.

PMID: 36636087 PMC: 9830355. DOI: 10.21037/jgo-22-348.